Semin Liver Dis 2009; 29(1): 102-120
DOI: 10.1055/s-0029-1192059
© Thieme Medical Publishers

Long-Term Care of the Liver Allograft Recipient

George Mells1 , James Neuberger2
  • 1The Liver Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
  • 2The Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom
Further Information

Publication History

Publication Date:
23 February 2009 (online)

ABSTRACT

As outcomes after liver transplant surgery continue to improve, management of the long-term consequences of the procedure and the associated immunosuppression become increasingly important. Liver allograft recipients have, compared with age and sex-matched controls, increased risk for cardiovascular and cerebrovascular events and death, for bone disease, and for some cancers. Early recognition and treatment of modifiable risk factors, especially of hypertension (present in up to 77% recipients), diabetes (in up to 22%), obesity (up to 40%), renal impairment (in up to 50%), and hyperlipidemia (in up to 66%) are necessary to maintain prolonged and healthy survival. Early recognition of de novo cancers (which occur in up to 26% recipients) indicates the need for additional monitoring for skin cancer and lymphoproliferative disorders, as well as cancers of the lung, colon, and upper gastrointestinal track. Early recognition of bone disease and appropriate intervention will allow introduction of strategies to reduce bone fracture. In this article, we review the evidence for the extent and treatment of these modifiable conditions in the allograft recipient.

REFERENCES

  • 1 McCaughan G W, O'Brien E, Sheil A G. A follow up of 53 adult patients alive beyond 2 years following liver transplantation.  J Gastroenterol Hepatol. 1993;  8 569-573
  • 2 Stegall M D, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity.  Transplantation. 1995;  60 1057-1060
  • 3 Guckelberger O, Bechstein W O, Neuhaus R et al.. Cardiovascular risk factors in long-term follow up after orthotopic liver transplantation.  Clin Transplant. 1997;  11 60-65
  • 4 Sheiner P A, Magliocca J F, Bodian C A et al.. Long-term medical complications in patients surviving > = 5 years after liver transplant.  Transplantation. 2000;  69 781-789
  • 5 Fernandez-Miranda C, Sanz M, dela Calle A et al.. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation.  Transpl Int. 2002;  15 556-562
  • 6 Johnston S D, Morris J K, Cramb R, Gunson B K, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation.  Transplantation. 2002;  27 901-906
  • 7 Neal D A, Tom B D, Luan J et al.. Is there disparity between risk and incidence of cardiovascular disease after liver transplant?.  Transplantation. 2004;  77 93-99
  • 8 Guckelberger O, Byram A, Klupp J et al.. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors.  Transpl Int. 2005;  18 967-974
  • 9 Mazuelos F, Abril J, Zaragoza C et al.. Cardiovascular morbidity and obesity in adult liver transplant recipients.  Transplant Proc. 2003;  35 1909-1910
  • 10 Ciccarelli O, Kaczmarek B, Roggen F et al.. Long-term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation.  Acta Gastroenterol Belg. 2005;  68 323-330
  • 11 Pruthi J, Medkiff K A, Esrason K T et al.. Analysis of causes of death in liver transplant recipients who survived more than 3 years.  Liver Transpl. 2001;  7 811-815
  • 12 Chobanian A V, Bakris G L, Black H R et al.. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report.  JAMA. 2003;  289 2560-2572
  • 13 Whitworth J A. World Health Organization, International Society of Hypertension Writing Group . World Health Organization-International Society of Hypertension guidelines for the management of hypertension.  J Hypertens. 2003;  21 1983-1992
  • 14 Guidelines committee . 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.  J Hypertens. 2003;  21 1011-1053
  • 15 Williams B, Poulter N R, Brown M J et al.. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.  J Hum Hypertens. 2004;  18 139-185
  • 16 Mailloux L U, Levey A S. Hypertension in patients with chronic renal disease.  Am J Kidney Dis. 1998;  32 S120-S141
  • 17 Saruta T. Mechanism of glucocorticoid-induced hypertension.  Hypertens Res. 1996;  19 1-8
  • 18 Mitchell B M, Clinton Webb R. Impaired vasodilatation and nitric oxide synthase activity in glucocorticoid-induced hypertension.  Biol Res Nurs. 2002;  4 16-21
  • 19 Morgan B J, Lyson T, Scherrer U, Victor R G. Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats.  Hypertension. 1991;  18 458-466
  • 20 Scherrer U, Vissing S F, Morgan B J et al.. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation.  N Engl J Med. 1990;  323 693-699
  • 21 Kurtz A, Della Bruna R, Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells.  Kidney Int. 1988;  33 947-953
  • 22 Nishiyama A, Kobori H, Fukui T et al.. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.  Hypertension. 2003;  42 754-760
  • 23 Avdonin P V, Cottet-Maire F, Afanasjeva G V, Loktionova S A, Lhote P, Ruegg U T. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells.  Kidney Int. 1999;  55 2407-2414
  • 24 Vetter M, Chen Z-J, Chang G-D, Che D, Liu S, Chang C-H. Cyclosporin A disrupts bradykinin signaling through superoxide.  Hypertension. 2003;  41 1136-1142
  • 25 Canzanello V J, Textor S C, Taler S J et al.. Renal sodium handling with cyclosporine A and FK506 after orthotopic liver transplantation.  J Am Soc Nephrol. 1995;  5 1910-1917
  • 26 Miller E R, Erlinger T P, Young D R et al.. Results of the diet, exercise, and weight loss intervention trial (DEW-IT).  Hypertension. 2002;  40 612-618
  • 27 Marterre W F, Hariharan S, First M R, Alexander J W. Gastric bypass in morbidly obese kidney transplant recipients.  Clin Transplant. 1996;  10 414-419
  • 28 Obarzanek E, Proschan M A, Vollmer W M et al.. Individual blood pressure responses to changes in salt intake: results from the DASH-sodium trial.  Hypertension. 2003;  42 459-467
  • 29 Keven K, Yalcin S, Canbakan B et al.. The impact of daily sodium intake on post-transplant hypertension in kidney allograft recipients.  Transplant Proc. 2006;  38 1323-1326
  • 30 Moore T J, Vollmer W M, Appel L J et al.. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial.  Hypertension. 1999;  34 472-477
  • 31 Xin X, He J, Frontini M G, Ogden L G, Motsamai O I, Whelton P K. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials.  Hypertension. 2001;  38 1112-1117
  • 32 Taler S J, Textor S C, Canzanello V J et al.. Hypertension after liver transplantation: a predictive role for pre-treatment hemodynamics and effects of isradipine on the systemic and renal circulations.  Am J Hypertens. 2000;  13 231-239
  • 33 Textor S C, Schwartz L, Wilson D J et al.. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension.  Hypertension. 1994;  23 I220-I224
  • 34 Galioto A, Angeli P, Guarda S et al.. Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial.  Transplant Proc. 2005;  37 1245-1247
  • 35 Neal D A, Brown M J, Wilkinson I B, Byrne C D, Alexander G J. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation.  Transplantation. 2004;  77 748-750
  • 36 Del Castillo D, Campistol J M, Guirado L et al.. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.  Kidney Int Suppl. 1998;  68 S135-S139
  • 37 Calviño J, Lens X M, Romero R, Sánchez-Guisande D. Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension.  Nephrol Dial Transplant. 2000;  15 82-86
  • 38 Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo J M. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin.  Kidney Int Suppl. 1998;  68 S130-S134
  • 39 Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.  Lancet. 2003;  362 1527-1545
  • 40 Chiffoleau A, Trochu J N, Veyrac G et al.. Rhabdomyolysis in cardiac transplant recipient due to verapamil interaction with simvastatin and cyclosporin treatment.  Therapie. 2003;  58 168-170
  • 41 Punch J D, Shieck V L, Campbell D A, Bromberg J D, Turcotte J G, Merion R M. Corticosteroid withdrawal after liver transplantation.  Surgery. 1995;  118 783-786
  • 42 Stegall M D, Everson G T, Schroter G et al.. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss.  Hepatology. 1997;  25 173-177
  • 43 Punch J D, Shieck V L, Campbell D A, Bromberg J S, Turcotte J G, Merion R M. Corticosteroid withdrawal after liver transplantation.  Surgery. 1995;  118 783-786
  • 44 Canzanello V J, Textor S C, Taler S J et al.. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506).  Liver Transpl Surg. 1998;  4 328-334
  • 45 Devlin J, Williams R, Neuhaus P et al.. Renal complications and development of hypertension in the European study of FK506 and cyclosporine in primary liver transplant recipients.  Transpl Int. 1994;  7 S22-S26
  • 46 Lucey M R, Abdelmalek M F, Gagliardi R et al.. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.  Am J Transplant. 2005;  5 1111-1119
  • 47 Neal D A, Gimson A E, Gibbs P, Alexander G J. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.  Liver Transpl. 2001;  7 533-539
  • 48 Emre S, Genyk Y, Schluger L K et al.. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.  Transpl Int. 2000;  13 73-78
  • 49 Herrero J I, Quiroga J, Sangro B et al.. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.  Liver Transpl Surg. 1999;  5 414-420
  • 50 Moreno J M, Rubio E, Gomez A et al.. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.  Transplant Proc. 2003;  35 1874-1876
  • 51 Schlitt H J, Barkmann A, Boker K HW et al.. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.  Lancet. 2001;  357 587-591
  • 52 Kreis H, Oberbauer R, Campistol J M for the Rapamune Maintenance Regimen Trial et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.  J Am Soc Nephrol. 2004;  15 809-817
  • 53 Falkenhaim M E, Cosio F G, Sedmark D D. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine.  Transplantation. 1996;  62 364-370
  • 54 Madsen J K, Sorenssen S S, Hansen H E, Pedersen E B. The effect of felodipine on renal function and blood pressure in cyclosporine-treated renal transplant patients during the first three months after transplantation.  Nephrol Dial Transplant. 1998;  13 2327-2334
  • 55 Venkat-Raman G, Feehally J, Elliott H L et al.. Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients.  Nephrol Dial Transplant. 1998;  13 2612-2616
  • 56 Kuypers D R, Neumayer H H, Fritsche L, Budde K, Rodicio J L, Vanrenterghem Y. Lacidipine Study Group . Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study.  Transplantation. 2004;  78 1204-1211
  • 57 Rahn K H, Barenbrock M, Fritschka E et al.. Effects of nitrendipine on renal function in renal-transplant patients treated with cyclosporine: a randomised trial.  Lancet. 1999;  354 1415-1420
  • 58 Seifeldin R, Marcos-Alvarez A, Lewis W D, Gordon F D, Jenkins R L. Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.  Clin Ther. 1996;  18 491-496
  • 59 Kamper A L, Straandgaard S, Leyssac P P. Effect of enalapril on the progression of chronic renal failure.  Am J Hypertens. 1992;  5 423-430
  • 60 Grekas D, Dioudis C, Kalevrosoglou I, Alivanis P, Derveniotis V, Tourkantonis A. Renal hemodynamics in hypertensive renal allograft recipients: effects of calcium antagonists and ACE inhibitors.  Kidney Int Suppl. 1996;  55 S97-S100
  • 61 Grekas D, Dioudis C, Kalevrosoglou I et al.. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.  Clin Nephrol. 1995;  44 299-302
  • 62 Shihab F S, Bennett W M, Tanner A M, Andoh T F. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.  Kidney Int. 1997;  52 660-673
  • 63 EBPG Expert Group on Renal Transplantation . European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension.  Nephrol Dial Transplant. 2002;  17 S25-S26
  • 64 Kasiske B L, Snyder J J, Gilbertson D, Matas A J. Diabetes mellitus after kidney transplantation in the United States.  Am J Transplant. 2003;  3 178-185
  • 65 Hjelmesaeth J, Hartmann A, Kofstad J et al.. Glucose intolerance after renal transplantation depends on prednisolone dose and recipient age.  Transplantation. 1997;  64 979-983
  • 66 Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systemic review and meta-analysis.  Am J Transplant. 2004;  4 583-595
  • 67 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33).  Lancet. 1998;  352 837-853
  • 68 The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
  • 69 Wheeler D C, Krentz A J. New-onset diabetes after transplantation.  Br J Hosp Med (Lond). 2007;  68 190-194
  • 70 Luther P, Baldwin Jr D. Pioglitazone in the management of diabetes mellitus after transplantation.  Am J Transplant. 2004;  4 2135-2138
  • 71 Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus.  Transplantation. 2005;  80 1402-1405
  • 72 Türk T, Pietruck F, Dolff S et al.. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.  Am J Transplant. 2006;  6 842-846
  • 73 Backman J T, Kajosaari L I, Niemi M, Neuvonen P J. Cyclosporine A increases plasma concentrations and effects of repaglinide.  Am J Transplant. 2006;  6 2221-2222
  • 74 Islam S I, Masuda Q N, Bolaji O O, Shaheen F M, Sheikh I A. Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients.  Ther Drug Monit. 1996;  18 624-626
  • 75 Sagedal S, Asberg A, Hartmann A, Bergan S, Berg K J. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients.  Clin Transplant. 1998;  12 553-556
  • 76 Cattaneo D, Bitto A, Baldelli S et al.. Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report.  Transplantation. 2008;  85 921-922
  • 77 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf Accessed November 3, 2006
  • 78 Sholter D E, Armstrong P W. Adverse effects of corticosteroids on the cardiovascular system.  Can J Cardiol. 2000;  16 505-511
  • 79 Deleuze S, Garrigue V, Delmas S et al.. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?.  Transplant Proc. 2006;  38 2311-2313
  • 80 Groth C G, Bäckman L, Morales J M et al.. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine.  Sirolimus European Renal Transplant Study Group . Transplantation. 1999;  67 1036-1042
  • 81 National Institute of Health .Your guide to lowering cholesterol with therapeutic lifestyle changes. Available at: http://www.nhlbi.nih.gov/health/public/heart/chol/chol_tlc.pdf Accessed November 3, 2006
  • 82 Imagawa D K, Dawson 3rd S, Holt C D et al.. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.  Transplantation. 1996;  62 934-942
  • 83 Taylor P J, Kubler P A, Lynch S V, Allen J, Butler M, Pillans P I. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.  Ann Pharmacother. 2004;  38 205-208
  • 84 Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.  Am J Transplant. 2006;  6 205-208
  • 85 Langone A J, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors.  Transplantation. 2006;  81 804-807
  • 86 Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients.  Am J Transplant. 2006;  6 770-774
  • 87 Puthenparumpil J J, Keough-Ryan T, Kiberd M, Lawen J, Kiberd B A. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population.  Transplant Proc. 2005;  37 1033-1035
  • 88 Chan T M, Cheng I K, Tam S C. Hyperlipidemia after renal transplantation: treatment with gemfibrozil.  Nephron. 1994;  67 317-321
  • 89 Bastani B, Robinson S, Heisler T et al.. Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy.  Clin Transplant. 1995;  9 340-348
  • 90 Lal S M, Hewett J E, Petroski G F, Van Stone J C, Ross Jr G. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.  Am J Kidney Dis. 1995;  25 616-622
  • 91 Pflugfelder P W, Huff M, Oskalns R, Rudas L, Kostuk W J. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.  J Heart Lung Transplant. 1995;  14 613-622
  • 92 Capone D, Stanziale P, Gentile A, Imperatore P, Pellegrino T, Basile V. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.  Am J Nephrol. 1999;  19 411-415
  • 93 Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients.  Am J Transplant. 2001;  1 382-386
  • 94 Hedman M, Neuvonen P J, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.  Clin Pharmacol Ther. 2004;  75 101-109
  • 95 Omar M A, Wilson J P, Cox T S. Rhabdomyolysis and HMG-CoA reductase inhibitors.  Ann Pharmacother. 2001;  35 1096-1107
  • 96 Lemahieu W P, Hermann M, Asberg A et al.. Combined therapy with atorvastatin and calcineurin inhibitors: no interaction with tacrolimus.  Am J Transplant. 2005;  5 2236-2243
  • 97 Ichimaru N, Takahara S, Kokado Y et al.. Changes in lipid metabolism and effects of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.  Atherosclerosis. 2001;  158 417-423
  • 98 Boissonnat P, Salen P, Guidollet J et al.. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.  Transplantation. 1994;  58 245-247
  • 99 Wierzbicki A S, Mikhailidis D P, Wray R et al.. Statin-fibrate combination: therapy for hyperlipidemia: a review.  Curr Med Res Opin. 2003;  19 155-168
  • 100 Frezza E E, Fung J J, van Thiel D H. Non-lymphoid cancer after liver transplantation.  Hepatogastroenterology. 1997;  44 1172-1181
  • 101 Jonas S, Rayes N, Neumann U et al.. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin.  Cancer. 1997;  80 1141-1150
  • 102 Jain A B, Yee L D, Nalesnik M A et al.. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.  Transplantation. 1998;  66 1193-1200
  • 103 Peyrègne V, Ducerf C, Adham M et al.. De novo cancer after orthotopic liver transplantation.  Transplant Proc. 1998;  30 1484-1485
  • 104 Galve M L, Cuervas-Mons V, Figueras J et al.. Incidence and outcome of de novo malignancies after liver transplantation.  Transplant Proc. 1999;  31 1275-1277
  • 105 Catena F, Nardo B, Liviano d'Arcangelo G et al.. De novo malignancies after organ transplantation.  Transplant Proc. 2001;  33(1–2) 1858-1859
  • 106 Haagsma E B, Hagens V E, Schaapveld M et al.. Increased cancer risk after liver transplantation: a population-based study.  J Hepatol. 2001;  34 84-91
  • 107 Xiol X, Guardiola J, Menendez S et al.. Risk factors for development of de novo neoplasia after liver transplantation.  Liver Transpl. 2001;  7 971-975
  • 108 Sanchez E Q, Marubashi S, Jung G et al.. De novo tumors after liver transplantation: a single-institution experience.  Liver Transpl. 2002;  8 285-291
  • 109 Herrero J I, Lorenzo M, Quiroga J et al.. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.  Liver Transpl. 2005;  11 89-97
  • 110 Oo Y H, Gunson B K, Lancashire R J, Cheng K K, Neuberger J M. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales.  Transplantation. 2005;  80(6) 759-764
  • 111 Boin I, Leonardi M I, Stucchi R B et al.. De novo posttransplantation nonlymphoproliferative malignancies in liver transplant recipients.  Transplant Proc. 2007;  39 3284-3286
  • 112 Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus.  Transplantation. 2000;  70 1335-1342
  • 113 Herrero J I, Lorenzo M, Quiroga J et al.. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.  Liver Transpl. 2005;  11 89-97
  • 114 Jain A, Reyes J, Kashyap R et al.. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.  Ann Surg. 2000;  232 490-500
  • 115 Jiménez C, Rodríguez D, Marqués E et al.. De novo tumors after orthotopic liver transplantation.  Transplant Proc. 2002;  34 297-298
  • 116 Duvoux C, Delacroix I, Richardet J P et al.. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis.  Transplantation. 1999;  67 418-421
  • 117 Benlloch S, Berenguer M, Prieto M et al.. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years?.  Am J Transplant. 2004;  4 596-604
  • 118 Herrero J I, Lucena J F, Quiroga J et al.. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy.  Am J Transplant. 2003;  3 1407-1412
  • 119 Jonas S, Rayes N, Neumann U et al.. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin.  Cancer. 1997;  80 1141-1150
  • 120 Jensen M K. Chromosome studies in patients treated with azathioprine and amethopterin.  Acta Med Scand. 1967;  182 445-455
  • 121 Sheil A G. Cancer in immune-suppressed organ transplant recipients: aetiology and evolution.  Transplant Proc. 1998;  30 2055-2057
  • 122 Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis.  Am J Med. 1993;  94 646-650
  • 123 Kanis J A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.  Osteoporos Int. 1994;  4 368-381
  • 124 Guichelaar M M, Schmoll J, Malinchoc M, Hay J E. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors.  Hepatology. 2007;  46 1198-1207
  • 125 Hamburg S M, Piers D A, van den Berg A P, Slooff M JH, Haagsma E B. Bone mineral density in the long term after liver transplantation.  Osteoporos Int. 2000;  11 600-606
  • 126 Giannini S, Nobile M, Ciuffreda M et al.. Long-term persistence of low bone density in orthotopic liver transplantation.  Osteoporos Int. 2000;  11 417-424
  • 127 Leidig-Bruckner G, Hosch S, Dodidou P et al.. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.  Lancet. 2001;  357 342-347
  • 128 Ninkovic M, Skingle S J, Bearcroft P W, Bishop N, Alexander G J, Compston J E. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation.  Eur J Gastroenterol Hepatol. 2000;  12 931-935
  • 129 Eastell R, Dickson E R, Hodgson S F et al.. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis.  Hepatology. 1991;  14 296-300
  • 130 Haagsma E B, Thijn C J, Post J G, Sloof M J, Gips C H. Bone disease after orthotopic liver transplantation.  J Hepatol. 1988;  6 94-100
  • 131 McDonald J A, Dunstan C R, Dilworth P et al.. Bone loss after liver transplantation.  Hepatology. 1991;  14 613-619
  • 132 Monegal A, Navasa M, Guañabens N et al.. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics.  Osteoporos Int. 2001;  12 484-492
  • 133 Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas P D. Bone loss after orthotopic liver transplantation.  Am J Med. 1994;  97 445-450
  • 134 Navasa M, Forns X, Sanchez V et al.. Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation.  J Hepatol. 1996;  25 129-134
  • 135 Leidig-Bruckner G, Hosch S, Dodidou P et al.. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.  Lancet. 2001;  357 342-347
  • 136 Collier J. Bone disorders in chronic liver disease.  Hepatology. 2007;  46 1271-1278
  • 137 Floreani A, Mega A, Camozzi V et al.. Is osteoporosis a peculiar association with primary biliary cirrhosis?.  World J Gastroenterol. 2005;  11 5347-5350
  • 138 Masuda S, Okano T, Osawa K, Shinjo M, Suematsu T, Kobayashi T. Concentrations of vitamin D-binding protein and vitamin D metabolites in plasma of patients with liver cirrhosis.  J Nutr Sci Vitaminol (Tokyo). 1989;  35 225-234
  • 139 Mass K, Quint E H, Punch M R, Merion R M. Gynecological and reproductive function after liver transplantation.  Transplantation. 1996;  62 476-479
  • 140 Kwan J T, Almond M K, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation.  Miner Electrolyte Metab. 1992;  18 166-168
  • 141 Lane N E. An update on glucocorticoid-induced osteoporosis.  Rheum Dis Clin North Am. 2001;  27 235-253
  • 142 Van Staa T P, Leufkens H G, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures.  J Bone Miner Res. 2000;  15 993-1000
  • 143 Cvetkovic M, Mann G N, Romero D F et al.. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo.  Transplantation. 1994;  57 1231-1237
  • 144 Collier J D, Ninkovic M, Compston J E. Guidelines on the management of osteoporosis associated with chronic liver disease.  Gut. 2002;  50(Suppl 1) i1-i9
  • 145 Shiomi S, Nishiguchi S, Kurooka H et al.. Cyclical etidronate for treatment of osteopenia in patients with cirrhosis of the liver.  Hepatol Res. 2002;  22 102-106
  • 146 Shiomi S, Masaki K, Habu D et al.. Calcitriol for bone disease in patients with cirrhosis of the liver.  J Gastroenterol Hepatol. 1999;  14 547-552
  • 147 Shiomi S, Masaki K, Habu D et al.. Calcitriol for bone loss in patients with primary biliary cirrhosis.  J Gastroenterol. 1999;  34 241-245
  • 148 Wolfhagen F H, van Buuren H R, den Ouden J W et al.. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.  J Hepatol. 1997;  26 325-330
  • 149 Guañabens N, Parés A, Ros I et al.. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.  Am J Gastroenterol. 2003;  98 2268-2274
  • 150 Crippin J S, Jorgensen R A, Dickson E R, Lindor K D. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment.  Am J Gastroenterol. 1994;  89 47-50
  • 151 Olsson R, Mattsson L A, Obrant K, Mellström D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis.  Liver. 1999;  19 188-192
  • 152 Floreani A, Zappala F, Fries W et al.. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.  J Clin Gastroenterol. 1997;  24 239-244
  • 153 O'Donnell S, Cranney A, Wells G A, Adachi J D, Reginster J Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis.  Cochrane Database Syst Rev. 2006;  3 CD005326
  • 154 Millonig G, Graziadei I W, Eichler D et al.. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.  Liver Transpl. 2005;  11(8) 960-966
  • 155 Bodingbauer M, Wekerle T, Pakrah B et al.. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation.  Am J Transplant. 2007;  7 1763-1769
  • 156 Hay J E, Malinchoc M, Dickson E R. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis.  J Hepatol. 2001;  34 292-298
  • 157 Crawford B A, Kam C, Pavlovic J et al.. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 2006;  144 239-248
  • 158 Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.  Osteoporos Int. 2006;  17 942-949
  • 159 Riemens S C, Oostdijk A, van Doormaal J J et al.. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen.  Osteoporos Int. 1996;  6 213-218
  • 160 Reeves H L, Francis R M, Manas D M, Hudson M, Day C P. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.  Liver Transpl Surg. 1998;  4(5) 404-409
  • 161 Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore C E. Pamidronate and osteoporosis prevention in liver transplant recipients.  Rheumatol Int. 2007;  27 251-256
  • 162 Isoniemi H, Appelberg J, Nilsson C, Mäkelä P, Risteli J, Höckerstedt K. Transdermal estrogen therapy improves lipid profile and osteoporosis in postmenopausal liver transplant patients.  Transplant Proc. 2001;  33 1472-1473

James NeubergerM.D. 

The Liver Unit, Queen Elizabeth Hospital

Birmingham B15 2TH, United Kingdom

Email: J.M.Neuberger@bham.ac.uk

    >